Integra LifeSciences (NSDQ:IART) yesterday touted positive findings from its Cadence total ankle system retrospective study and closed enrollment ahead of schedule for two post-market studies of the device.
The study reported that patients treated with Cadence while suffering from end-stage arthritis experienced improvements in quality of life, functional measures and pain. The results were presented during the American Orthopaedic Foot & Ankle Society meeting in Chicago last week.
In the U.S., 131 patients were enrolled at 12 study centers between August 2017 and February 2019. The company expects two-year follow-up data to be published in 2021.
“The physicians involved in the Cadence total ankle system post-market studies are excited that the implant has been performing very well,” lead investigator Dr. Tim Daniels of the University of Toronto said in prepared remarks. “The undertaking of these studies signifies Integra LifeSciences’ commitment to scientific rigor and ensuring patient outcomes are being properly assessed and followed.”
The Cadence system is designed to accommodate various patient anatomies, reduce potential clinical complications and address common challenges associated with ankle arthroplasty procedures.
Integra Lifesciences also hit its target enrollment for Cadence system post-market studies in the U.S. and Europe, both ahead of schedule. The company said they are the first multi-center prospective studies conducted on the Cadence system, which was launched in 2016.
Shares of IART were down -0.1% at $60.94 per share in late-afternoon trading today.
